Where does Inventisbio Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Inventisbio Co., Ltd. ranks #13,499 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Inventisbio Co., Ltd. hold?

Inventisbio Co., Ltd. holds 22 US utility patents granted between 2020 and 2025, spanning 6 technology areas.

What is Inventisbio Co., Ltd.'s Innovation Score?

Inventisbio Co., Ltd. has an Innovation Score of 45.6 out of 100 (top 23% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Inventisbio Co., Ltd. focus on?

Inventisbio Co., Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 22 patents, ranking #884 of 6,058 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Inventisbio Co., Ltd.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Inventisbio Co., Ltd..

What does claim depth mean for Inventisbio Co., Ltd.'s patents?

Inventisbio Co., Ltd.'s patents average 16.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Inventisbio Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Inventisbio Co., Ltd.

USPTO PatentsView assignee record - 22 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Inventisbio ranks #13,499 of 49,997 tracked US assignees by granted-patent volume, with 22 patents across 6 technology areas.

#13,499
of 49,997 US assignees by volume: Top 23%
by Innovation Score (45.6/100): 16.9
avg claims per patent

USPTO PatentsView assignee plate

Corpus R13499 · Foreign Corporation #13,499 · 22 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 22 grants
MID-PACK #13,499/49,997
PHOTO-FINISH Imasen Electric…
CPC-NARROW A61P · 6 areas
INNOV-PAR 45.6/100
CLAIMS-RICH 16.9 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Imasen Electric Industrial Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Inventisbio’s 45.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.8 pts (24%) Velocity 16.0 pts (35%) Breadth 8.7 pts (19%) Claim depth 10.1 pts (22%)

Qualcomm Incorporated · highest

85
Inventisbio · this assignee

46
3D Lighting… · lowest

7

What this shows Inventisbio's Innovation Score is 45.6/100 (top 23% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Inventisbio?

Each dot is one of Inventisbio’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Inventisbio’s own 16.9 claims/patent is ABOVE the 9.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Inventisbio vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Inventisbio's grants concentrate

Inventisbio Co., Ltd. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (5 grants) versus a trough of 1 in 2020. By volume, Inventisbio sits between Importla, LLC and Impressions Vanity Company.

Inventisbio's three-year grant acceleration

Inventisbio Co., Ltd. shows 12 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Importla

22
Infinitesima

22
International Cur…

22
Inthesmart

22
Inzicontrols

22
Ishida Europe

22
Imasen Electric I…

22
Impressions Vanity

22
Inventisbio ◀

22

What this shows Inventisbio holds 22 patents at rank #13,482, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Inventisbio

By rank, the assignees closest to #13,482 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Inventisbio's primary technology class.

Inventisbio's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 23% higher than 77% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Inventisbio Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	4.5%
2021	4	18.2%
2022	4	18.2%
2023	3	13.6%
2024	5	22.7%
2025partial year	5	22.7%

Which technologies does Inventisbio Co., Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 22

C07D - Heterocyclic Compounds 22

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 19

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 9

C07C - Acyclic OR Carbocyclic Compounds 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Inventisbio Co., Ltd.'s patent record in context - here's where to go next.

Inventisbio Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #13,499 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Inventisbio Co., Ltd. against Importla, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.